Clinical Trial Update: 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for the 18F-PSMA-1007 PET/CT imaging in prostate cancer (ACCESS Trial), planned from 2022 to 2028, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA-1007 (PSMA-1007 radiotracer)

Snippet

Sponsor: University of Alberta | Conditions: Prostate Cancer | Phase 3 | Status: RECRUITING